826 related articles for article (PubMed ID: 26819103)
1. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
3. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
[TBL] [Abstract][Full Text] [Related]
4.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
5. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
6. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
Jullien M; Reichert T; D'Anella P; Castinetti F; Barlier A; Brue T; Taieb D; Cuny T
Ann Endocrinol (Paris); 2020 Feb; 81(1):39-43. PubMed ID: 31982106
[TBL] [Abstract][Full Text] [Related]
8. Functional imaging in differentiating bronchial masses: an initial experience with a combination of (18)F-FDG PET-CT scan and (68)Ga DOTA-TOC PET-CT scan.
Kumar A; Jindal T; Dutta R; Kumar R
Ann Nucl Med; 2009 Oct; 23(8):745-51. PubMed ID: 19784877
[TBL] [Abstract][Full Text] [Related]
9. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance and impact on patient management of
Paquet M; Gauthé M; Zhang Yin J; Nataf V; Bélissant O; Orcel P; Roux C; Talbot JN; Montravers F
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1710-1720. PubMed ID: 29532101
[TBL] [Abstract][Full Text] [Related]
12. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
Kroiss A; Putzer D; Frech A; Decristoforo C; Uprimny C; Gasser RW; Shulkin BL; Url C; Widmann G; Prommegger R; Sprinzl GM; Fraedrich G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
[TBL] [Abstract][Full Text] [Related]
13. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [
Yadav D; Ballal S; Yadav MP; Tripathi M; Roesch F; Bal C
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):860-869. PubMed ID: 31754796
[TBL] [Abstract][Full Text] [Related]
15. Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1.
Kornaczewski Jackson ER; Pointon OP; Bohmer R; Burgess JR
J Clin Endocrinol Metab; 2017 Jun; 102(6):1926-1933. PubMed ID: 28323985
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
[TBL] [Abstract][Full Text] [Related]
17. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
18. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
Hope TA; Pampaloni MH; Nakakura E; VanBrocklin H; Slater J; Jivan S; Aparici CM; Yee J; Bergsland E
Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
[TBL] [Abstract][Full Text] [Related]
20. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
